We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
Intralesional alfa-2a interferon therapy for basal cell carcinoma.
Cancer Letters 1995 May 9
Basal cell carcinoma (BCC) is an epithelial tumour of the skin that arises from basal cells of the epidermis and its appendages. There are some therapeutic models for BCC, and one of these is intralesional interferon. Thirteen patients with histopathologically-proven BCC on their faces or trunk were treated with intralesional interferon alfa-2a. Only 2 of 13 patients required surgery due to insufficient improvement. All the others were completely cured in 12 to 36 weeks. We concluded that intralesional interferon therapy of sufficient dose and duration for noduloulcerative and superficial BCC is an encouraging alternative to surgery and other treatment models.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app